Topical Omega-3 for Dry Eye: Does Delivery Change the Result?

Fish oil has failed its biggest dry-eye test. In the multicenter DREAM randomized trial of roughly 350 people, oral omega-3 supplements did not improve dry-eye outcomes more than refined olive oil placebo; an extension study found no penalty when participants stopped taking omega-3. For dry eye, swallowing EPA and DHA has no established clinical benefit.

That leaves a narrower, more interesting question: could the same fatty acids work if a drop placed them directly on the tear film? The answer is not yet known. Small human studies of topical omega-3 show improvements in tear-film stability and corneal staining, but they cannot separate the effect of omega-3 from the lubricating vehicle that carries it.

Why delivery might matter

Dry eye disease involves disrupted tear-film homeostasis: an unstable lipid layer can increase evaporation, raise tear osmolarity, damage the ocular surface, and feed inflammation. EPA and DHA have plausible roles in cell membranes and lipid layers, and they have anti-inflammatory properties. A 2023 study of systemic omega-3 levels and corneal measures also found an association between higher systemic omega-3 status and favorable corneal nerve structure and function. That association supports biological plausibility; it does not show that omega-3 treats dry eye, or that topical DHA reaches a therapeutic concentration in human tears.

Oral dosing sends fatty acids through intestinal absorption, hepatic processing, and the circulating lipid pool before they might reach the ocular surface. No demonstrated transport system preferentially sends EPA or DHA to the tear film. A topical formulation avoids those steps. It still faces a more mundane obstacle: tears turn over, and a compound may wash away before it has a meaningful effect.

What the topical studies found

A 2022 PRISMA-compliant systematic review screened 152 publications and included five human studies, totaling 419 participants, plus five animal studies. The human studies covered idiopathic dry eye, contact-lens discomfort, and dry eye after corneal crosslinking. They used different formulations, comparison treatments, populations, and outcome measures, so the reviewers appropriately did not pool the results into a single effect size.

Across those studies, tear break-up time (TBUT) and corneal fluorescein staining showed the most consistent favorable signals. TBUT measures how quickly the tear film becomes unstable after a blink; corneal staining tracks surface epithelial damage. Symptom scores on the Ocular Surface Disease Index improved where studies reported them. Schirmer testing, which estimates aqueous tear production, produced inconsistent results. That pattern fits an effect on evaporative dry eye and the lipid layer more than a reliable increase in tear secretion.

The review included a flaxseed-oil drop trial and DHA-containing drops used two to four times daily for two to four months. Some studies used active comparators, including hyaluronic acid, Refresh Optive Advanced, and F6H8. None used an inert placebo. Animal experiments reported changes in ocular-surface inflammatory signaling and immune-cell infiltration, but animal findings cannot establish a human clinical effect.

A water-free DHA drop in routine practice

The most direct clinical test of this delivery idea was a 2022 prospective multicenter observational study at two German sites. It enrolled 36 people with defined evaporative dry eye: TBUT of 8 seconds or less, OSDI of at least 25, corneal fluorescein staining of 11 or less on the NEI scale, meibomian gland dysfunction score of at least 3, and Schirmer's test of at least 5 mm.

Participants used NovaTears+Omega-3 for eight weeks. The preservative-free, water-free drop combines 0.2% algae-derived DHA with perfluorohexyloctane, also called SFA. This low-surface-tension vehicle spreads across the eye and integrates with the existing tear-film lipid layer without aqueous dilution or conventional emulsification. At eight weeks, TBUT, corneal staining, meibomian gland dysfunction score, OSDI, Schirmer's test, and a 10-domain symptom visual analog scale all improved from baseline.

Those within-person improvements are encouraging proof of concept, not proof that DHA caused them. The study had no placebo group, no SFA-only group, and no masking; it also had 36 participants and no formal sample-size calculation. Dry-eye symptoms and several clinical measures can improve with expectation, regression to the mean, and treatment attention. The publication does not provide a controlled estimate that can isolate the DHA component.

The vehicle is the central unresolved question

Perfluorohexyloctane-based drops without omega-3 can lubricate the ocular surface in evaporative dry eye. That makes the observed improvement in the DHA/SFA study hard to interpret: DHA may add benefit, SFA may account for most of it, or both may contribute. The existing studies cannot distinguish among those explanations.

The need for a concurrent control is more than a methodological ritual. A 2024 randomized, double-blind, placebo-controlled trial of an oral multi-ingredient supplement containing lutein, zeaxanthin, curcumin, and vitamin D3 reported improved dry-eye symptoms and tear production versus placebo. It did not study omega-3 or eye drops. It does show that dry-eye outcomes can respond in placebo-controlled nutritional trials, which makes uncontrolled improvement a weak basis for assigning credit to one ingredient.

Nor should omega-3's general anti-inflammatory reputation fill the gap. In a 2025 randomized, double-blind crossover study of adults with abdominal obesity, marine EPA/DHA and plant linoleic acid produced some differing changes, including systolic blood pressure, but no difference in circulating inflammatory markers. The study did not assess dry eye or topical delivery. It is a reminder that fatty-acid effects depend on the tissue, population, and endpoint under study.

What the oral trials actually settled

The oral evidence deserves the most weight because DREAM was large, randomized, and placebo-controlled. As summarized in the topical omega-3 systematic review, oral omega-3 did not significantly outperform refined olive oil placebo on dry-eye clinical outcomes, and stopping supplementation in the extension study did not worsen outcomes compared with continuing it. The supplied reports do not provide extractable primary effect estimates or confidence intervals for a precise numerical comparison, but the direction and statistical conclusion are clear: oral omega-3 has not earned a place as a dry-eye treatment.

That failure does not disprove a topical route. It does set the evidentiary bar. A plausible route of delivery is a reason to run a trial, not a substitute for one.

The practical verdict

People taking fish oil specifically to relieve dry eye should not expect benefit based on the current oral trial evidence. A water-free DHA/SFA eye drop is a reasonable hypothesis for evaporative dry eye, especially because topical studies have most consistently improved TBUT and corneal staining rather than aqueous tear production. Its evidence remains preliminary, short term, and formulation-specific: human topical studies have lasted no longer than four months, and no long-term efficacy or safety evidence answers whether benefit persists.

The study that would answer the real question needs three masked groups: SFA plus omega-3, SFA alone, and an inert placebo, in a sufficiently large evaporative-dry-eye population.

Until that trial exists, topical omega-3 is best described as biologically plausible with early clinical signals. It is not established evidence-based treatment, and no self-experiment can tell a user whether any relief came from DHA, the SFA vehicle, or the usual variability of dry eye.